14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
GSUN vs UBXG: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Golden Sun Health Technology Group Limited Class A (GSUN) is the stronger overall head-to-head candidate over U-BX Technology Ltd. (UBXG) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GSUN carries a Unified Composite Score of 40.3/100 (SELL) at $0.12 (N/M Forward P/E, -10.2% operating margin), whereas UBXG carries 48.9/100 (HOLD) at $5.03 (N/M Forward P/E, -87.6% operating margin).
Composite vs. Pillar Nuance: While UBXG currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. GSUN 40.3/100 SELL), GSUN captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-10.2% vs. -87.6% operating margin) and revenue trajectory (+30.1% vs. -32.6% YoY).
Technical & Structure Timing Caution: GSUN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.1); meanwhile UBXG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GSUN vs UBXG. Trailing 12-month operating profitability (GSUN -10.2% vs UBXG -87.6%) and valuation multiples (GSUN N/M vs UBXG N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Advertising Agencies value chain with $9.2M market capitalization and -87.6% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ GSUN vs UBXG Key Questions & Quantitative Answers
As of Nov 20, 2026, Golden Sun Health Technology Group Limited Class A (GSUN) is the stronger overall head-to-head candidate over U-BX Technology Ltd. (UBXG) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GSUN carries a Unified Composite Score of 40.3/100 (SELL) at $0.12 (N/M Forward P/E, -10.2% operating margin), whereas UBXG carries 48.9/100 (HOLD) at $5.03 (N/M Forward P/E, -87.6% operating margin). Composite vs. Pillar Nuance: While UBXG currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. GSUN 40.3/100 SELL), GSUN captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-10.2% vs. -87.6% operating margin) and revenue trajectory (+30.1% vs. -32.6% YoY). Technical & Structure Timing Caution: GSUN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.1); meanwhile UBXG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
GSUN leads the Growth & Scale pillar: GSUN posts +30.1% YoY revenue growth and -73.7% YoY earnings growth on $40M TTM revenue (1.8% gross margin, -10.2% operating margin), compared with UBXG at -32.6% YoY revenue growth and -88.4% YoY earnings growth on $24M TTM revenue (0.3% gross margin, -87.6% operating margin). On trailing 12-month operating scale, GSUN generates $40M in USD-normalized revenue versus $24M for UBXG. In operating R&D and SG&A reinvestment, GSUN deploys 12.0% of Rev ($4.9M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for UBXG.
GSUN and UBXG trade at balanced relative valuation multiples. GSUN trades at N/M Forward P/E, 0.3x Trailing P/E, N/M PEG, and N/M EV/Revenue (-9.8% EBITDA margin), whereas UBXG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.4x EV/Revenue (-53.4% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GSUN (-247.2% ROE) versus UBXG (-46.6% ROE) capital efficiency.
In options market volatility and institutional positioning, GSUN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.59β · 59% Vol realized risk). By comparison, UBXG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (10.23β · 225% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.